Here’s how to treat coronavirus, according to research – Daily Nation

By XINHUAMore by this Author

China has released the seventh version of the diagnosis and treatment guideline on the novel coronavirus disease (Covid-19).

Here are some drugs and therapies that have been recommended by the guideline, and some medicines that have been found to have the potential to defeat the virus and have entered clinical trials.

Chloroquine Phosphate, a widely used anti-malaria and autoimmune disease drug, has been used for more than 70 years.

The drug has been used in treating 285 critically ill Covid-19 patients in a hospital in Wuhan, and no obvious adverse reactions have been found so far.

In the latest version of the treatment guideline, Chloroquine Phosphate is recommended for Covid-19 patients from 18 to 65.

The amount for patients over 50 kg is 500 mg per dose twice a day for seven days.

The guideline also noted that patients should take less than three antiviral drugs.

Tocilizumab, with the common brand name Actemra, is an injectable synthetic protein that blocks the effects of IL-6 in patients with rheumatoid arthritis.

IL-6 is a protein that the body produces when there is inflammation.The latest version of the guideline suggests the use of Tocilizumab in patients with an increasing level of IL-6 and with extensive lesions in both lungs or severe symptoms.

Chinese researchers have found that a cause of death for severe and critically ill patients infected with the novel coronavirus is cytokine storm, an overreaction of the immune system.

These patients are found with a higher level of IL-6 in their blood.

Last month, the increasing level of IL-6 was recommended as a warning sign that the patient's situation could possibly deteriorate.

Currently, the drug is under clinical trials in 14 hospitals in Wuhan and a total of 272 severe patients had been treated with Tocilizumab as of March 5.

Convalescent plasma, processed from the plasma collected from recovered Covid-19 patients, contains a large number of protective antibodies.

As of February 28, 245 Covid-19 patients have received the therapy and 91 cases have shown improvement in clinical indicators and symptoms.

According to health authorities, plasma therapy has proved safe and effective.

4. TRADITIONAL CHINESE MEDICINE

Traditional Chinese Medicine (TCM) has been proven effective in treating Covid-19 patients.

With TCM treatment, patients with mild symptoms have seen their fever or cough alleviated, according to medical experts.

For severely ill patients, TCM helped relieve symptoms and restore blood oxygen saturation, preventing the patients' conditions from developing into critically ill cases.

TCM decoction Qingfei Paidu Soup has been recommended to medical institutions nationwide on February 6 after data analysis on 214 cases.

As of February 29, the decoction is used in 66 designated hospitals in 10 provincial-level regions in China.

Favipiravir, an influenza drug available on overseas markets, has been put in a parallel controlled study in Shenzhen, Guangdong Province, with 80 patients enlisted.

The initial outcome of the trial shows the drug has relatively obvious efficacy and low adverse reactions.

Experts have suggested expanding the trial to further observe and study its effect.

Remdesivir, developed against Ebola infections by American pharmaceutical company Gilead Sciences, has shown fairly good antiviral activity against the novel coronavirus at the cellular level.

Cao Bin, a respiratory expert who is leading the Remdesivir programme, said on Wednesday that two trials for Remdesivir are going on smoothly and China will share the data with the international community after the programme is completed.

Clinical studies on stem cell therapy, which can inhibit the overreaction of the body's immune system, have also been carried out to treat severe patients.

As of February 21, four patients who have received the therapy have been discharged from hospital, and the trial is expected to be further expanded. Currently, three kinds of stem cells mesenchymal, lung and embryonic stem cells are used in treatments.

Researchers usually inject stem cell products into the lungs.

Meanwhile, the Chinese Academy of Sciences has developed a new stem cell drug, CAStem, which has shown promising results in animal experiments.

The research team has applied for urgent assessment by the National Medical Products Administration.

Approvals by the ethics committee, and clinical observation and evaluation, are in progress.

Several research and trials on applying stem cells to treat Covid-19 patients have been carried out in the country.

Continue reading here:
Here's how to treat coronavirus, according to research - Daily Nation

Lonza looks to Cocoon to drive cell therapy shift – Bioprocess Insider – BioProcess Insider

Lonza has partnered with several academic clinical centers to assess the manufacture of cell therapies in a decentralized setting using its automated Cocoon point-of-care (PoC) platform.

Swiss contract development and manufacturing organization (CDMO) Lonza announced independent research collaborations with Stanford University School of Medicine, Fred Hutchinson Cancer Research Center, and Parker Institute for Cancer Immunotherapy. The collaborations will see the tech transfer of cell therapy manufacturing processes developed at the respective research institutes into the Cocoon platform.

The Cocoon system is a patient-scale, closed, and automated manufacturing system intended for the manufacture of a variety of autologous cell therapy protocols, including CAR-T, but also tumor-infiltrating lymphocytes (TILs) and Mesenchymal stem cells (MSCs).

Fred Hutchinson Cancer Research Center is one of several institutes collaborating with Lonza on the Cocoon tech. Image: Joe Mabel/creativecommons

It is clear that manufacturing autologous cell therapies requires a paradigm shift, Eytan Abraham, head of personalized medicine at Lonza, told Bioprocess Insider. The current manual processes will not allow these therapies to scale and some therapies are more challenging to manufacture and deliver in a centralized manufacturing model.

He added the Cocoon technology forms part of a wider program of R&D, platform development and process improvement at Lonza aimed at serving the increasing number of patient-scale, personalized therapies.

The platform offers advantages including increased number of unit operations in one system, faster process set-up due to its plug and play cassette, reduced clean room space required and reduced staff for handling.

The news comes a year after Lonza inked a collaboration with Israels Sheba Medical Center intended to confirm the benefits of using the Cocoon system to make autologous cell therapies in a PoC environment.

The Cocoon system was developed by Octane Biotech. Lonza acquired an 80% stake in the company in 2018, and is now driving the development of patient-scale manufacturing including autologous cell therapies with Cocoon, according to Abraham.

Lonza has been working with Octane on the Cocoon platform for about four years, three of these as an evaluation phase, and as a majority shareholder only since November 2018, he told us. It was critical for us to assure that the technology is mature enough and meets the needs of our varied customer base.

While Lonza is offering the Cocoon system as a tech offering, it has also integrated the platform into its cell and gene therapy offering and installed the equipment at its Houston, Texas site.

The plan is to use the Cocoon technology in either centralized manufacturing in our own facilities as a CDMO service, or at our customers facilities as a technology. A decentralized model of hubs and point of care is also possible. As such, we are working with different partners to enable all three options, and we believe that all three will be viable and important.

Continued here:
Lonza looks to Cocoon to drive cell therapy shift - Bioprocess Insider - BioProcess Insider

Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Treatment Of COVID-19 Lung Disease – BioSpace

NEW YORK, March 10, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited(Nasdaq: MESO; ASX:MSB) today announced that it plans to evaluate its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19) in the United States, Australia, China and Europe. The Company is in active discussions with various government and regulatory authorities, medical institutions and pharmaceutical companies to implement these activities.

Mortality in COVID-19 infected patients with the inflammatory lung condition acute respiratory distress syndrome (ARDS) is reported to approach 50%, and is associated with older age, co-morbidities such as diabetes, higher disease severity, and elevated markers of inflammation.1 Current therapeutic interventions do not appear to be improving in-hospital survival.1

Remestemcel-L has potential for use in the treatment of ARDS, which is the principal cause of death in COVID-19 infection.1 This is supported by recently published results from an investigator-initiated clinical study conducted in China which reported that allogeneic MSCs cured or significantly improved functional outcomes in all seven treated patients with severe COVID-19 pneumonia.2

Additionally, in post-hoc analyses of a 60-patient randomized controlled study in chronic obstructive pulmonary disease (COPD), remestemcel-L infusions were well tolerated, significantly reduced inflammatory biomarkers, and significantly improved pulmonary function in those patients with elevated inflammatory biomarkers. Since the same inflammatory biomarkers are also elevated in COVID-19, these data suggest that remestemcel-L could be useful in the treatment of patients with ARDS due to COVID-19.The COPD study results have been submitted for presentation at an international conference, with full results to be submitted for publication shortly.

Remestemcel-L is being studied in numerous clinical trials across several inflammatory conditions, including in elderly patients with lung disease and adults and children with steroid-refractory acute graft versus host disease (aGVHD).3-5 This product candidate is currently being reviewed by the United States Food and Drug Administration (FDA) for potential approval in the treatment of children with steroid-refractory aGVHD.

Remestemcel-L Remestemcel-L is being developed for rare pediatric and adult inflammatory conditions. It is an investigational therapy comprising culture-expanded MSCs derived from the bone marrow of an unrelated donor and is administered in a series of intravenous infusions. Remestemcel-L is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in several diseases by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

Intellectual PropertyMesoblasts intellectual property (IP) portfolio encompasses over 1,000 patents or patent applications in all major markets and includes the use of MSCs obtained from any source for patients with acute respiratory distress syndrome (ARDS),and for inflammatory lung disease due to coronavirus (COVID-19), influenza and other viruses. Additionally, these patents cover Mesoblasts manufacturing processes that yield industrial-scale cellular medicines.This IP position is expected to provide Mesoblast with substantial commercial advantages as it develops its product candidates for these conditions.

References1. Liu Y et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. Medrxiv 2020; https://doi.org/10.1101/2020.02.17.200241662. Leng Z, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia[J]. Aging and Disease, 10.14336/AD.2020.02283. Kurtzberg J et al. Annual Meeting of the American Society for Transplantation Cell Therapy, 2020.4. Chaudhury S et al. A Phase 3 Single-Arm, Prospective Study of Remestemcel-L, Ex-Vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Steroid Refractory Acute GVHD in Pediatric Patients. Biol Blood Marrow Transplant 2018; 24:S119S290.5. Kurtzberg J et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant. 2014 Feb;20(2):229-35.

About MesoblastMesoblast Limited (Nasdaq: MESO; ASX: MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblasts proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has filed a Biologics License Application to the United States Food and Drug Administration (FDA) to seek approval of its product candidate RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GvHD). Remestemcel-L is also being developed for other rare diseases. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. If approved, RYONCIL is expected to be launched in the United States in 2020 for pediatric steroid-refractory acute GVHD. Two products have been commercialized in Japan and Europe by Mesoblasts licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking StatementsThis announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward- looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblasts preclinical and clinical studies, and Mesoblasts research and development programs; Mesoblasts ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblasts ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblasts product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblasts product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblasts ability to enter into and maintain established strategic collaborations; Mesoblasts ability to establish and maintain intellectual property on its product candidates and Mesoblasts ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblasts expenses, future revenues, capital requirements and its needs for additional financing; Mesoblasts financial performance; developments relating to Mesoblasts competitors and industry; and the pricing and reimbursement of Mesoblasts product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblasts actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For further information, please contact:

Read more here:
Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Treatment Of COVID-19 Lung Disease - BioSpace

Duke researchers may have found a path to correcting loss of smell – WRAL Tech Wire

DURHAM Is it possible for an adult brain to make new nerve cells? Scientists have debated this question for decades, with many concluding that neuron-making stops after childhood, or around the age of 13.

However, a research team recently rocked the debate again after finding a thriving neuron nursery in a section of adult human nose tissue, the olfactory neuroepithelium. Neurons are the specialized cells in the brain designed to transmit information to other nerve cells and muscles. The olfactory area of the nose houses the neural receptors that give us the ability to smell.

Previously, studies had been limited to nasal tissue samples from mice. In the human samples used in the current study, the researchers found that immature neurons or baby neurons produced by stem cells represented more than half of the neurons in the tissue samples, suggesting that new neurons were produced in the tissue. The findings were published in the journalNature Neuroscience. The finding has implications for correcting conditions that cause smell damage or loss, and add insights for treating the nervous system as a whole.

We do not fully understand why people lose their sense of smell, which can occur for many reasons, and our data sets provide a wealth of information about the cell populations present in adult olfactory tissue, saidBrad Goldstein, M.D., Ph.D., an associate professor at Duke University and vice chair for research in theDepartment of Head and Neck Surgery and Communication Sciences, senior author of the study. This is an important step in developing treatment strategies for conditions when this tissue may be damaged.

Approximately one in eight Americans over age 40up to 13.3 million peoplehave measurable smell dysfunction, according to the National Institute on Deafness and Other Communication Disorders.

It will be very useful to use this window to analyze samples from people with conditions in which the nervous system has degeneration, such as Alzheimers disease, said Goldstein. Alzheimers is of particular interest, since these patients lose their sense of smell quite early in the disease process, and we have few treatments for Alzheimers disease. So, it may make sense to look carefully at regions of the olfactory system in these patients.

Hiroaki Matsunami, Ph.D., a professor in the Department of Molecular Genetics and Microbiology and co-author on the paper, noted that while the researchers werent able to observe the neurons being made because of the nature of human samples, the molecular makeup of the immature neurons in the sample provide strong evidence that they were made in the nose during adulthood.

Because the nose is exposed to the external environment, it might be possible we could one day collect these neuronal stem cells from patients and use them to treat their own brain disorders, said Matsunami. It is not outside of the realm of possibility.

Other co-authors on the paper include Michael A. Durante, Stefan Kurtenbach, Zoukaa B. Sargi, J. William Harbour, Rhea Choi, Sarah Kurtenbach, and Garrett M. Goss.

(C) Duke University

Original post:
Duke researchers may have found a path to correcting loss of smell - WRAL Tech Wire

Biotech company makes new discovery in hormone imbalance research – The Badger Herald

A biotech startup achieved a significant breakthrough in the development of therapies that seek to reverse age related hormone imbalances.

JangoBio, a Madison based startup, announced the breakthrough in a press release Feb. 18. The company successfully created organ-like tissue clusters capable of producing ovarian and testicular hormones.

University of Wisconsin endocrinology professor and JangoBio CEO Craig Atwood founded the company in 2014 to address limitations in the current approach to treating hormone imbalances that occur with age.

As ovaries and testes start to decline in function theres a loss of dozens of different hormones which are very important for maintaining tissue health, Atwood said.

Flu cases in Madison rapidly outpace past seasonsThe number of flu cases increased substantially in Madison, compared to cases recorded during the same season last year, according Read

Atwood said the current limitations are the ability to only be able to give back one or two sex steroids. Atwood added JangoBios strategy of utilizing cell based therapy allows for the synthesis of dozens of hormones to get the entire axis back into balance.

In the bodies of humans or animals, the therapy being developed by JangoBio would involve the injection of organoids, Atwood said. Organoids are tiny, self-organized three-dimensional tissue cultures that are derived from stem cells, according to the Harvard Stem Cell Institute.

The new developments allow JangoBio to begin testing the therapy in animal models, Atwood said. Such testing would be necessary to demonstrate the therapys efficacy and would be an important step towards introducing it in the human market, Atwood said.

JangoBio plans on commercializing the veterinary applications of the therapy by introducing it to companion animals within a year and begin clinical trials on humans shortly after, the COO Bill Kohl said. Starting with companion animals would allow the company to test and refine the therapy while simultaneously generating funding to pursue human applications.

After decrease in opioid overdoses in Madison, UW, city takes steps to sustain downward trendAfter Madison saw a 10% decrease in opioid overdoses in 2019 from the previous year, city officials and University of Read

We can utilize that data and research that results from the animal side to refine the treatments for humans while at the same time sustaining our research without going out and getting additional investor money, Kohl said.

Atwood said a colleague previously determined reproductive hormones played a role in the neurodegeneration that occurs with Alzheimers disease. Atwood added the observation led them to develop the Reproductive Cell Cycle theory of aging which maintains that the improper regulation in sex hormones drives the gradual deterioration of bodily function that occurs with age.

Atwood said he founded JangoBio as a means of translating his findings into a therapy that could benefit both humans and animals.

The funding required to move such a product forward is more easily obtainable in the private sector than the public sector, Atwood said. Its really tied into finding sufficient capital to be able to move this vision forward to the point where it has practical applications and utility in humans and animals.

JangoBio was able to establish itself through a small business grant from the National Institute of Health for more money than they initially requested in their application, Kohl said. The grant was especially validating given the vigorous vetting applicants undergo from both scientists and people in industry, Kohl said.

The company raised $2 million from investors in a seed financing round, Atwood said.

Now were positioned to national investment firms for the next round of growth as we develop commercialization in the animals, Kohl said.

The broad potential of organoid therapy is what prompted Kohl to join the JangoBio team in the first place.

Atwood approached Kohl five years ago to begin and manage the business aspects of JangoBio so Atwood could focus on the research and scientific development, Kohl said. Like a number of roles on the executive board, the COO position is unpaid.

Theres rarely the opportunity in life for you to get to be involved in something that will have so much impact, Kohl said. The long term [goal] is going to be to stave off and mitigate age related diseases.

Kohl said by reversing hormone decline and restoring the tissues responsible for keeping hormones at their peak youthful levels, JangoBio has every indication from animal models this is going to have that type of impact.

UW-led research reports high level trust in science among American public over past decadesIn a recent study conducted by University of Wisconsin professor Dominique Brossard and her team, Americans indicated a relatively stable Read

Applications for JangoBios hormone therapy go beyond humans and companion animals, Kohl said. The agriculture industry could potentially apply the therapy to extend breeding times for stead animals and production time for dairy animals, Kohl said.

While Atwood considers the company to be cutting edge in the development of hormone based organoids, Atwood said a number of companies are conducting parallel research in developing similar stem cell based therapies, particularly in the field of Type 1 diabetes.

JangoBio is one of 10 other biotech companies in the Madison area, all part of a thriving biotech industry born as a result of research conducted at UW, according to the Wisconsin State Journal.

Follow this link:
Biotech company makes new discovery in hormone imbalance research - The Badger Herald

Longevity And Anti-Senescence Therapy Market Overview, Consumption, Supply, Demand & Insights – Kentucky Journal 24

The global longevity and anti-senescence therapies market should grow from $329.8 million in 2018 to $644.4 million by 2023 with a compound annual growth rate (CAGR) of 14.3% during 2018-2023.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Get Sample Copy Of The Report@https://www.trendsmarketresearch.com/report/sample/11698

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

Report Includes:

71 data tables and 40 additional tables An overview of the global longevity and anti-senescence therapy market Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics A look at the clinical trials and expected launch of anti-senescence products Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Request For Report Discount@https://www.trendsmarketresearch.com/report/discount/11698

Summary

Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for life expectancy in the demography. Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and a rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED. An increasing geriatric population across the globe will generate huge growth prospectus to the market.

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others. Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED. Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics. For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.

Report Analysis@https://www.trendsmarketresearch.com/report/analysis/BCC/global-longevity-and-anti-senescence-therapy-market

Follow this link:
Longevity And Anti-Senescence Therapy Market Overview, Consumption, Supply, Demand & Insights - Kentucky Journal 24

Shingles vaccine makes an impact around the world and right here in Rockford – Rockford Register Star

Although most people are aware that the College of Medicine graduates 55 physicians each year, many of whom eventually practice in Winnebago County, the research enterprise of the campus is less well known. In particular, a remarkable breakthrough in the prevention of shingles occurred two years ago which should make every Rockfordian proud. Shingles is a painful skin rash that can cause itching and excruciating pain, and occasionally blindness.

Without a preventive vaccine it will impact 1 out of every 3 people and can be particularly serious for those who are elderly or have impaired immune systems. The exciting news is that a vaccine developed right here in Rockford is providing protection to millions of people around the world.

Two years ago, the U.S. Food and Drug Administration approved a new vaccine to prevent herpes zoster or shingles, a painful condition caused by the chickenpox virus. After childhood chickenpox, the virus becomes dormant in neurons and may reactivate in adults to cause shingles. The vaccine, marketed by GSK under the brand name ShingrixTM, is now the recommended vaccine for adults over age 50. It is not only safer, but is more effective than the existing live vaccine.

Abbas Vafai, Ph.D., the scientist who developed the Shingrix vaccine, worked on its development when he was an associate professor of microbiology at the University of Illinois College of Medicine Rockford from 1990 to 1997 and also had worked on the vaccine at the University of Colorado. The U.S. Food & Drug Administration approved the vaccine for use in October 2017. Since then, the Centers for Disease Control has recommended Shingrix for all adults over age 50.

Because of this, its use for all adults 50 years and older is warranted the only problem has been getting enough of it made to meet the worldwide demand. Vaccine shortage have been felt in Rockford and throughout the country.

We are incredibly excited about Dr. Vafais success with vaccine development and are extremely proud that a vaccine developed on the Rockford campus of the University of Illinois College of Medicine is now impacting the health of people worldwide.

Because some of the work on the vaccine was conducted on the Rockford campus, a portion of the profits will go to the College of Medicine Rockford. The total of what the College of Medicine Rockford and its Department of Biomedical Sciences may receive in royalties over the course of the seven years is predicted to be over $10 million. These are dollars that allow us to continue to educate tomorrows scientists and physicians and support cutting-edge research.

As the UIC Health Sciences Campus-Rockford on Parkview Avenue continues to thrive and grow, so does the Rockford community. In fact, an economic impact study conducted in 2016 indicated the campus had an impact of over $58.2 million to the Rockford Metro Area the equivalent of 898 jobs.

For those whose doctor recommends the Shingrix vaccine, they can expect the vaccine, given in two doses, will prevent what could be a serious and painful condition. The vaccine is also extremely effective in preventing a consequence of shingles called postherpetic neuralgia. Postherpetic neuralgia occurs in 10% to 18% of individuals who have shingles and is characterized by a severe chronic pain condition that can last for years.

Biomedical research at the College of Medicine continues to explore new ways to improve health and prevent disease. State-of-the-art research in the areas of prostate cancer, lung cancer, eradication of parasitic infections, improving the longevity of joint replacements and stem cell treatment of severe debilitating neurologic diseases, occurs daily on campus. With the support of our community, the next major medical breakthrough could again come from the University of Illinois College of Medicine Rockford and its team of researchers in the Department of Biomedical Sciences and other academic departments.

Dr. Alex Stagnaro-Green is the regional dean of the University of Illinois College of Medicine at Rockford.

Read the rest here:
Shingles vaccine makes an impact around the world and right here in Rockford - Rockford Register Star

Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA -…

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), markedly exceeding the FDA-agreed threshold for the primary efficacy endpoint. While an overview of preliminary data submitted to FDA was made public on December 4, 2019 in a press release from the company, all patients have now completed treatment and trial enrollment has been closed. Narsoplimab is Omeros human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2).

In recent meetings with FDA focused on clinical as well as chemistry, manufacturing and controls (CMC) data, FDA confirmed important aspects of Omeros rolling Biologics License Application (BLA) for narsoplimab in HSCT-TMA. The BLA continues on its clear path to completion.

The efficacy threshold agreed with FDA, the updated results from the 28-patient trial, and highlights of the recent FDA meetings are the following:

Primary Endpoint

Secondary Endpoints

Safety

The treated population had multiple high-risk features that portend a poor outcome, including the persistence of HSCT-TMA despite modification of immunosuppression (which was a criterion for entry into the trial), graft-versus-host disease, significant infections, non-infectious pulmonary complications and neurological findings. Patients in the trial had a high expected mortality rate, with 93% of them having multiple risk factors.

The efficacy and safety data from the pivotal trial with narsoplimab are encouraging, said Miguel-Angel Perales, M.D., Deputy Chief of the Adult Bone Marrow Transplantation Service and Director of the Adult Stem Cell Transplantation Fellowship at Memorial Sloan Kettering Cancer Center. Given the trials stringent response criteria across laboratory markers and organ function, the complete response rate seen with narsoplimab is remarkable, as is the 100-day survival. There currently is no approved treatment for HSCT-TMA. Current therapy is generally limited to supportive care and withdrawal of drugs critical for GVHD prophylaxis. Not only could narsoplimab become central to the treatment of HSCT-TMA, it might well allow us to maintain that needed GVHD prophylaxis.

Complete clinical trial data will be presented by Dr. Perales later this month at the Annual Meeting of the European Society for Blood and Marrow Transplantation in Madrid.

Recent FDA Meeting Highlights and CMC Updates

The non clinical sections of our BLA have been submitted, our CMC campaign is progressing well with process validation and commercial lots already manufactured, and our pivotal trial is complete, stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. The efficacy threshold agreed with FDA reflects both the primary endpoints stringent response criteria and the poor outcomes expected in the patients enrolled in our trial. Of course, were very pleased that the response rates and confidence intervals seen with narsoplimab are well above that efficacy threshold. We look forward to continuing to work closely with regulators to make the drug commercially available to transplanters and their patients in the U.S. and internationally as quickly as possible.

In addition to its HSCT-TMA program, Omeros is enrolling its narsoplimab Phase 3 clinical trials for immunoglobulin A (IgA) nephropathy and atypical hemolytic uremic syndrome (aHUS). Narsoplimab has been granted, for both HSCT-TMA and IgA nephropathy, FDAs breakthrough therapy designation as well as orphan drug designations from FDA and the European Medicines Agency. The drug also holds FDAs fast-track designation for aHUS.

Primary Efficacy Endpoint

To be considered a responder, a patient must achieve the primary endpoint of complete HSCT-TMA response defined by improvement in laboratory markers and improvement in clinical status.

Laboratory Markers

Clinical Status

About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-mediated disorders and substance abuse. In addition, the company has a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.

About HSCT-TMA

Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) is a significant and often lethal complication of stem cell transplants. This condition is a systemic, multifactorial disorder caused by endothelial cell damage induced by conditioning regimens, immunosuppressant therapies, infection, GvHD, and other factors associated with stem cell transplantation. Endothelial damage, which activates the lectin pathway of complement, plays a central role in the development of HSCT-TMA. The condition occurs in both autologous and allogeneic transplants but is more common in the allogeneic population. In the United States and Europe, approximately 25,000 to 30,000 allogeneic transplants are performed annually. Recent reports in both adult and pediatric allogeneic stem cell transplant populations have found an HSCT-TMA incidence of approximately 40 percent, and high-risk features may be present in up to 80 percent of these patients. In severe cases of HSCT-TMA, mortality can exceed 90 percent and, even in those who survive, long-term renal sequalae are common. There is no approved therapy or standard of care for HSCT-TMA.

About Narsoplimab

Narsoplimab, also known as OMS721, is an investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target and the effector enzyme of the lectin pathway of complement. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection. Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2.

Phase 3 clinical programs are in progress for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), in immunoglobulin A (IgA) nephropathy, and in atypical hemolytic uremic syndrome (aHUS). The FDA has granted narsoplimab breakthrough therapy designations for HSCT-TMA and for IgA nephropathy; orphan drug status for the prevention (inhibition) of complement-mediated thrombotic microangiopathies, for the treatment of HSCT-TMA and for the treatment of IgA nephropathy; and fast track designation for the treatment of patients with aHUS. The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in HSCT and for treatment of primary IgA nephropathy.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the safe harbor created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as anticipate, believe, can, could, estimate, expect, goal, intend, likely, look forward to, may, on track, plan, potential, predict, project, prospects, scheduled, should, slated, targeting, will, would and similar expressions and variations thereof. Forward-looking statements, including statements regarding anticipated regulatory submissions, expectations regarding regulatory exclusivities, the timing and results of ongoing or anticipated clinical trials, and the therapeutic application of Omeros investigational product, are based on managements beliefs and assumptions and on information available to management only as of the date of this press release. Omeros actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, availability and timing of data from clinical trials and the results of such trials, unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading Risk Factors in the companys Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on March 2, 2020. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, whether as a result of any new information, future events or otherwise, except as required by applicable law.

Dr. Miguel-Angel Perales has received compensation from Omeros for advisory services.

More here:
Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA -...

Stem Cell Alopecia Treatment Market 2020 Size, Shares, Key Players, Demand, Supply, Growth and Forecast to 2026 – 3rd Watch News

New Jersey, United States,-The Stem Cell Alopecia Treatment Market report was created with experience and knowledge by market analysts and researchers. It is a phenomenal compilation of important studies that examine the competitive landscape, segmentation, geographic expansion and sales growth, production and consumption of the Stem Cell Alopecia Treatment market. Players can use the reports accurate market data and numbers, as well as statistical studies, to understand the current and future growth of the Stem Cell Alopecia Treatment market. The report includes CAGR, market share, sales, gross margin, value, volume and other key market numbers that provide a clear picture of the growth of the Stem Cell Alopecia Treatment market.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=15102&utm_source=3WN&utm_medium=001

Top Key Players of the Stem Cell Alopecia Treatment Market Research Report:

Our analysts have used advanced primary and secondary research techniques and tools to prepare this report. The sources and research tools we use are extremely reliable. New players can also use this research study to develop business strategies and learn about future market challenges. We offer a complete competitive analysis that includes a detailed company profile of the main players, a study of the nature and characteristics of the supplier landscape and other important studies.

Leading Regions

The research study contains important results and insights from our monitoring and analysis of the market for Stem Cell Alopecia Treatment industry. We have provided key data points, including divestments, launches, enhancements, partnerships, mergers, acquisitions, and other strategic initiatives by players in the Stem Cell Alopecia Treatment market. The report also includes price developments for regional markets and an analysis of important market events at regional and global levels. Our analysis enables you to make informed decisions in the market for Stem Cell Alopecia Treatment in terms of acquisitions, inventory, prices and production. We enable you to offer your opponents tough competition by providing fast, actionable market information in real time.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102&utm_source=3WN&utm_medium=001

Table of Content

1 Introduction of Stem Cell Alopecia Treatment Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Alopecia Treatment Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Alopecia Treatment Market, By Deployment Model

5.1 Overview

6 Stem Cell Alopecia Treatment Market, By Solution

6.1 Overview

7 Stem Cell Alopecia Treatment Market, By Vertical

7.1 Overview

8 Stem Cell Alopecia Treatment Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Alopecia Treatment Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Customized Report in your Inbox within 24 hours @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/?utm_source=3WN&utm_medium=001

Highlights of the Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Stem Cell Alopecia Treatment Market Size, Stem Cell Alopecia Treatment Market Growth, Stem Cell Alopecia Treatment Market Forecast, Stem Cell Alopecia Treatment Market Analysis, Stem Cell Alopecia Treatment Market Trends, Stem Cell Alopecia Treatment Market

Our Trending Reports

Flexible Workspace Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Go here to see the original:
Stem Cell Alopecia Treatment Market 2020 Size, Shares, Key Players, Demand, Supply, Growth and Forecast to 2026 - 3rd Watch News

10 things to know about stem cell therapy – Newsd.in

New Delhi: The usage of stem cells to cure or treat a disease or repair the injured tissue is defined as stem cell therapy. The best example of the stem cell treatment is seen in patients suffering from restoring the vision of the damaged eyes, grafting of the skin in severe burnt conditions.

Stem cell treatments for brain or neural diseases like Parkinsons and Alzheimers disease, multiple sclerosis, preventing heart strokes, curing diabetes, kidney disorders, autism, and spinal cord injuries are progressively making their way.

Undifferentiated cells that are able to differentiate and transform into any type of cells of the body when and where needed. They have an enormous potential to repair, heal and regenerate. Stem cells come from blood, bone marrow, umbilical cord blood and adipose tissue.

Autologous stem cell therapy: Patient receives stem cells from his/her own body

Allogeneic stem cell therapy: Patient receives the stem cells donated by another individual

Autologous stem cell therapy is better than allogeneic stem cell therapy as chances of mismatching are not there and they pose the minimum risk of immune rejection. Also, no side effects or adverse effects are seen as a persons own blood cells are used. They start the healing process immediately in a natural way.

The usage of stem cells to cure or treat a disease or repair the injured tissue is defined as stem cell therapy. Stem cells can be obtained from the bone marrow, adipose tissues etc. Due to their tremendous potential to prevent and to treat various health conditions and to repair the injured tissues global research investigation is continuously being done as to explore the maximum advantage of these cell lines.

The best example of the stem cell treatment is seen in patients suffering from restoring the vision of the damaged eyes, grafting of the skin in severe burnt conditions. Stem cell treatments for brain or neural diseases like Parkinsons and Alzheimers disease, multiple sclerosis, preventing heart strokes, curing diabetes, kidney disorders, autism, and spinal cord injuries are progressively making their way.

Depending upon the disease, different stem cell source can be used in a specific condition. The procedure may involve the extraction of stem cells from adipose tissue-derived stem cells with the combination of PRP (Platelet-rich plasma) or can be obtained from bone marrow that can differentiate into progenitor cells that differentiate into various other tissues which can help in the therapy.

The stem cells are isolated from the bone marrow or adipose tissues followed by their processing and enrichment under sterile conditions. These activated stem cells are placed back into the patients body at the target site for repairing the damaged tissue. It is necessary that the stem cells are injected in the specific area of injury as only then the desired results will be achieved.

Adipose stem cells are preferred over bone marrow stem cells as they are easy to isolate and contain a higher number of stem cells.

The stem cells injections are gaining much interest because it is devoid of the painful procedure, takes less time in comparison to surgery, there are no host and recipient rejections as stem cells are harvested from the patients body itself and a targeted delivery system is available.

The stem cells obtained are processed in a sophisticated stem cell lab and after activation is inserted back into the host with the help of intravenous, intramuscular, intraarterial, intradermal and intrathecal injections as per the requirement of the treatment process.

What is the use of anaesthetics and why? Usually, local anaesthetics are used during a stem cell procedure to numb the area but sometimes general anaesthesia is also given while extracting the stem cells from bone marrow. But it is necessary to find out what anaesthetic your doctor uses during orthopaedic stem cell treatments.

A number of anaesthetics have been found to kill the stem cells thus; the treatments end result will greatly depend on the use of anaesthetics. Some anaesthetics very well sync with the stem cell and hence, aid in the treatment.

Stem cells are to be extracted and processed in a clean room, under aseptic conditions maintaining a controlled environment. The doctor should explain the entire process and the number of viable stem cells infused into the patient during the process. Also, the precision of the injections to provide good quality of stem cells at the site of injury will help in better and faster recovery of the patients damaged area.

Cost of the treatment and its duration varies from one patient to another. The disease which needs to be cured, the severity, age factor, health condition, etc, define the duration of the therapy. One may respond during the treatment phase itself while the other may show results after a few sessions or weeks. Depending upon the disease diagnosed, the stem cells extracted, duration of the therapy, other adjuvants used in the process, the cost of the stem cell therapy can vary.

It is essential that after the stem cell therapy the patient should visit the stem cell doctor for recuperation therapies. The primary goals of such therapy is the prevention of secondary complications, analysis of the recovery of motor, sensory and all the bodily functioning, psychological support/counselling for depression, mood swings or anxiety etc. and reintegration into the community.

There can be different sets of precautions which need to be followed at various steps for the recovery of the damaged tissues. The treatment and post-treatment conditions may vary from person to person depending upon the disease and the severity.

Stem cell therapy has shown results in treating serious ailments like leukaemia, grafting tissues, autism, orthopaedic conditions and skin problems etc. Stem Cell Therapy has been successfully used in the treatment of around 80 serious disorders.

Survival rates among patients who received stem cell treatment are significantly high, whether cell donors are related or unrelated to them. With the ongoing research around the world, scientists are exploring new possibilities in which a number of life-threatening diseases can be prevented and cured hence, the stem cells have proved to be promising in the near future as many aspects are yet to be revealed.

Read: Egg stem cells do not exist, says researchers

-IANS

Follow this link:
10 things to know about stem cell therapy - Newsd.in